Table 1 TOPK expression is a prognostic marker for cancer
From: T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
Site | Cancer type | Methodology | Findings | References |
|---|---|---|---|---|
Prostate | Neuroendocrine carcinoma, acinar adenocarcinoma | Transcriptome profiling, IHC | One of the top 10 genes overexpressed in small cell carcinoma | |
Adenocarcinoma | IHC, qRT-PCR | Upregulation associated with age, Gleason score, clinicopathological stage, metastatic spread, survival and PSA failure. Predictor for biochemical recurrence-free survival | ||
Prostatic adenocarcinoma | IHC, immunoblot, microarray | Expression correlates with lack of tissue differentiation, disease aggression and metastatic spread | ||
Prostatic adenocarcinoma | Custom qRT-PCR Microarray | Cancer/testis antigen for prostate cancer, expression correlates with Gleason score but not age, stage, or preoperative PSA | ||
Prostatic adenocarcinoma | IHC | Expression correlates with stage > T2c and Gleason score ≥ 8, PSA > 20 ng/ml | ||
Liver | Hepatocellular carcinoma, cholangiocarcinoma | IHC | High expression in cholangiocarcinoma, lower expression in hepatocellular carcinoma. Low expression associated with poor prognosis in CCA | |
Hepatocellular carcinoma | qRT-PCR; immunoblot | Upregulation in all HCC cases | ||
Head and neck | Oral squamous cell carcinoma | IHC | Low expression associated with poor prognosis in young patients, high expression in older patients associated with poorly differentiated tumours, smokers, and late-stage disease. | |
Ovarian | Epithelial ovarian cancer | IHC, Immunoblot, qRT-PCR | High expression associated with poor progression-free survival and overall survival in early-stage cancer; Transactivation in EOC, less in borderline malignancy tumours | |
Brain | Glioblastoma multiforme | Immunoblot, IHC qRT-PCR | Upregulated in all GBM samples | |
Lung | Adenocarcinoma | IHC | High expression associated with poorly differentiated tumours, metastatic spread, high-TNM stage and reduced overall survival. Patients with combination of high TOPK and mutp53 had lowest prognosis | |
Haematological | Primary AML | qRT-PCR, immunoblotting | TOPK detected in 9/12 samples; 3/3 ALL samples and in plasmocytoma and blastic type mantle cell lymphoma. Weak expression in peripheral blood stem cells | |
Gastric | Gastric carcinoma | IHC, immunoblotting | Expression independently correlated with poor outcome | |
Oesophageal | Oesophageal squamous cell carcinoma | qRT-PCR, IHC, immunoblotting | Expression independently correlated with poor outcome | |
Colorectal | Colorectal carcinoma | IHC tissue microarray | No relationship between VEGFa gene amplification and TOPK expression/gene status |
